Literature DB >> 15545170

Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.

A Larsen1, N Hovdenak, A Karlsdottir, T Wentzel-Larsen, O Dahl, M K Fagerhol.   

Abstract

BACKGROUND: Non-invasive diagnostic tools to evaluate the severity of acute, radiation-induced proctitis are not readily available. The faecal excretion of eight markers of gut inflammation was therefore examined. Five proteins and three lipid derivates were analysed in sequential stool samples taken before and during radiation therapy.
METHODS: Stool samples from 15 patients with prostate cancer scheduled for radiation therapy were examined. Pretreatment and in-treatment samples (2nd and 6th weeks) were measured by enzyme-linked immunosorbent assay (ELISA) (calprotectin, lactoferrin, transferrin, leukotriene B4, prostaglandin E2, thromboxane B2 and TNF alpha) or nephelometry (alpha 1-antitrypsin).
RESULTS: Calprotectin and lactoferrin concentrations increased significantly during radiation treatment (P = 0.0005 and P = 0.019). Transferrin was detected in only 9 out of 45 samples. There were no changes in tumour necrosis factor alpha (TNF alpha), leukotriene B4, prostaglandin E2 and thromboxane B2 during treatment. alpha 1-antitrypsin could not be detected in any sample.
CONCLUSIONS: This study indicates that faecal calprotectin and lactoferrin concentrations could be markers of acute, radiation-induced proctitis. Patient compliance and stability of the markers make this a promising method for clinical research. Eicosanoids could be measured in stool samples, but the concentrations did not increase with increasing radiation dose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545170     DOI: 10.1080/00365520410003614

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.

Authors:  Renata D'Incà; Elisabetta Dal Pont; Vincenza Di Leo; Antonio Ferronato; Walter Fries; Maria Grazia Vettorato; Diego Martines; Giacomo Carlo Sturniolo
Journal:  Int J Colorectal Dis       Date:  2006-07-13       Impact factor: 2.571

Review 2.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

3.  The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats.

Authors:  Özgür Dandin; Mehmet Levhi Akin; Ahmet Ziya Balta; Ergün Yücel; Dursun Özgür Karakaş; Sezai Demirbaş; Sevim Özdemir; Apdullah Haholu
Journal:  Indian J Surg       Date:  2013-05-05       Impact factor: 0.656

4.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

Authors:  Jun-Ying Xiang; Qin Ouyang; Guo-Dong Li; Nan-Ping Xiao
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

5.  Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Tom Marcelissen; Kobe Reynders; Jarno Melenhorst; Joep G H van Roermund; Ludy Lutgens
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-25

6.  A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

Authors:  Sendhilnathan Ramalingam; Sharareh Siamakpour-Reihani; Lauren Bohannan; Yi Ren; Alexander Sibley; Jeff Sheng; Li Ma; Andrew B Nixon; Jing Lyu; Daniel C Parker; James Bain; Michael Muehlbauer; Olga Ilkayeva; Virginia Byers Kraus; Janet L Huebner; Thomas Spitzer; Jami Brown; Jonathan U Peled; Marcel van den Brink; Antonio Gomes; Taewoong Choi; Cristina Gasparetto; Mitchell Horwitz; Gwynn Long; Richard Lopez; David Rizzieri; Stefanie Sarantopoulos; Nelson Chao; Anthony D Sung
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.